Chuck Bramlage

Chuck Bramlage Chief Executive Officer

Chuck Bramlage came up through the commercial ranks at Merck and GSK, before going into start-up biotech companies and restructuring older pharma companies. His last company, Pearl Therapeutics was sold to AZ in 2013 for up to $1.15B. He left AZ at the end of 2016, and joined Yamo in 2017, where they are developing L1-79 for ASD (autism). He and his teams have launched 28 products in 15 therapeutic areas.